Growing community of inventors

Allschwil, Switzerland

Andreas Krause

Average Co-Inventor Count = 3.00

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 9

Andreas KrauseJasper Dingemanse (7 patents)Andreas KrauseMatthias Hoch (4 patents)Andreas KrauseCyrille Lescop (3 patents)Andreas KrauseFriedrich Raulf (1 patent)Andreas KrauseAndreas Scherer (1 patent)Andreas KrauseDetlef Niese (0 patent)Andreas KrauseAndreas Krause (7 patents)Jasper DingemanseJasper Dingemanse (10 patents)Matthias HochMatthias Hoch (4 patents)Cyrille LescopCyrille Lescop (12 patents)Friedrich RaulfFriedrich Raulf (1 patent)Andreas SchererAndreas Scherer (1 patent)Detlef NieseDetlef Niese (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Actelion Pharmaceuticals Ltd (3 from 217 patents)

2. Idorsia Pharmaceuticals Ltd (3 from 77 patents)

3. Vanda Pharmaceuticals Inc. (1 from 108 patents)

4. Novartis Ag (3,923 patents)

5. Novartis Pharma Gmbh (8 patents)


7 patents:

1. 12336980 - Dosing regimen for a selective S1P1 receptor agonist

2. 11834443 - Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

3. 11771683 - Dosing regimen for a selective S1Preceptor agonist

4. 11390615 - Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox

5. 10857134 - Dosing regimen for a selective S1Preceptor agonist

6. 10836754 - Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

7. 10220023 - [object Object]

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/1/2026
Loading…